Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Buys 25,836 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock in a transaction that occurred on Monday, June 29th. The stock was acquired at an average price of $3.44 per share, for a total transaction of $88,875.84. Following the transaction, the insider directly owned 71,842 shares of the company’s stock, valued at $247,136.48. The trade was a 56.16% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.23 per share, for a total transaction of $21,818.65.

Shuttle Pharmaceuticals Price Performance

Shares of SHPH stock opened at $3.40 on Thursday. The stock’s 50 day simple moving average is $5.93 and its two-hundred day simple moving average is $10.74. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90. The company has a market cap of $2.18 million, a PE ratio of -0.07 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter worth approximately $124,000. Boothbay Fund Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $26,000. Finally, Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the third quarter valued at $357,000. 4.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Shuttle Pharmaceuticals presently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .